Physician profile
Kendra Manning
NPI 1770910184
$5,628.29
in general payments reported to CMS, 2019-2025
25 companies · $1,120 in 2025
The $1,120 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,285 · 2022: $1,620 · 2023: $856 · 2024: $747 · 2025: $1,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,723.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,181.31 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $806.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $722.66 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $633.84 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $504.64 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $347.37 | 2022-2025 | |
| Corcept Therapeutics | $292.14 | 2025 | Korlym |
| Amgen INC. | $259.40 | 2021-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $128.96 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.08 | 2021-2022 | |
| Exact Sciences Corporation | $92.59 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $88.83 | 2021 | |
| Pfizer INC. | $88.01 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $78.58 | 2022 | |
| Mylan Specialty L.P. | $55.69 | 2024 | Yupelri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.89 | 2021-2022 | |
| Vbi Vaccine (Delaware) INC. | $32.71 | 2022 | |
| Agios Pharmaceuticals, INC. | $28.77 | 2025 | Pyrukynd |
| Ardelyx, INC. | $26.10 | 2024 | Ibsrela |
| Dexcom, INC. | $23.30 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $21.79 | 2021 | |
| Glaxosmithkline, LLC. | $21.59 | 2025 | Arexvy, Shingrix |
| Seqirus USA INC | $20.32 | 2024 | Fluad, Flucelvax |
| Amarin Pharma, INC. | $18.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Manning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.